Print

Genocea Biosciences Initiates a Phase 1/2a Study With Its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2)  
8/15/2012 10:06:54 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2) infection.
//-->